Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms

doi:10.3748/wjg.v22.i15.3962

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6852)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

453

WORD

372

HTML

3547

Figures (1-5)

265

Tables (1-1)

233

Sum=4870

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

779

Download

1203

Sum=1982

Apr 21, 2016 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Apr 21, 2016; 22(15): 3962-3968
Published online Apr 21, 2016. doi: 10.3748/wjg.v22.i15.3962

Full Size Figure Download Figure

Figure 3 Expression of Mcl-1 in cells after treatment with different concentrations of norcantharidin.

Citation: Ren J, Li G, Zhao W, Lin L, Ye T. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms. World J Gastroenterol 2016; 22(15): 3962-3968
URL: https://www.wjgnet.com/1007-9327/full/v22/i15/3962.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i15.3962